Q-omics provides the consensus-scored REC8 profile across patient tissues and cancer cell-line models. REC8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, REC8 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, REC8 RNA expression shows 18,133 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where REC8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REC8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REC8 survival associations across molecular data types. REC8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REC8 RNA expression–survival associations across cancer types. High REC8 expression shows unfavorable associations in ACC and KIRC, but favorable associations in SKCM, MESO, BRCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for REC8 RNA expression.
This table summarizes REC8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for REC8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REC8 shows lower tumor expression in KICH, KIRP, KIRC, LUAD and LUSC and higher tumor expression in UCEC. The KICH box plot shows higher REC8 RNA expression in normal versus tumor tissue (log2 FC = −3.188, t-test p < 0.001).
This table shows molecular features associated with REC8 in patient tissues and cancer cell lines. In patient samples, REC8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, REC8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
